Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Inhibikase Therapeutics stock | $5.35
Learn how to easily invest in Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc is a biotechnology business based in the US. Inhibikase Therapeutics shares (IKT) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibikase Therapeutics employs 3 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Inhibikase Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IKT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Inhibikase Therapeutics stock price (NASDAQ: IKT)Use our graph to track the performance of IKT stocks over time.
Inhibikase Therapeutics shares at a glance
|Latest market close||$5.35|
|52-week range||$2.03 - $11.80|
|50-day moving average||$3.15|
|200-day moving average||$5.33|
|Wall St. target price||$15.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
Buy Inhibikase Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Inhibikase Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Inhibikase Therapeutics price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||91.07%|
|3 months (2021-04-30)||2.29%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Inhibikase Therapeutics financials
|Revenue TTM||$1.8 million|
|Gross profit TTM||$-195,334|
|Return on assets TTM||-51.46%|
|Return on equity TTM||-296.13%|
|Market capitalisation||$57.9 million|
TTM: trailing 12 months
Shorting Inhibikase Therapeutics shares
There are currently 259,541 Inhibikase Therapeutics shares held short by investors – that's known as Inhibikase Therapeutics's "short interest". This figure is 3.8% up from 250,015 last month.
There are a few different ways that this level of interest in shorting Inhibikase Therapeutics shares can be evaluated.
Inhibikase Therapeutics's "short interest ratio" (SIR)
Inhibikase Therapeutics's "short interest ratio" (SIR) is the quantity of Inhibikase Therapeutics shares currently shorted divided by the average quantity of Inhibikase Therapeutics shares traded daily (recently around 1.4 million). Inhibikase Therapeutics's SIR currently stands at 0.19. In other words for every 100,000 Inhibikase Therapeutics shares traded daily on the market, roughly 190 shares are currently held short.
To gain some more context, you can compare Inhibikase Therapeutics's short interest ratio against those of similar companies.
However Inhibikase Therapeutics's short interest can also be evaluated against the total number of Inhibikase Therapeutics shares, or, against the total number of tradable Inhibikase Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibikase Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inhibikase Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0351% of the tradable shares (for every 100,000 tradable Inhibikase Therapeutics shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inhibikase Therapeutics.
Find out more about how you can short Inhibikase Therapeutics stock.
Inhibikase Therapeutics share dividends
We're not expecting Inhibikase Therapeutics to pay a dividend over the next 12 months.
Inhibikase Therapeutics overview
Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia. .
Stocks similar to Inhibikase Therapeutics
Inhibikase Therapeutics in the news
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Inhibikase To Start Testing Its Parkinson's Candidate In Patients
Frequently asked questionsWhat percentage of Inhibikase Therapeutics is owned by insiders or institutions?
Currently 21.151% of Inhibikase Therapeutics shares are held by insiders and 14.322% by institutions. How many people work for Inhibikase Therapeutics?
Latest data suggests 3 work at Inhibikase Therapeutics. When does the fiscal year end for Inhibikase Therapeutics?
Inhibikase Therapeutics's fiscal year ends in December. Where is Inhibikase Therapeutics based?
Inhibikase Therapeutics's address is: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 What is Inhibikase Therapeutics's ISIN number?
Inhibikase Therapeutics's international securities identification number is: US45719W1062
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert